Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Overview

cited authors

Dagogo-Jack, Samuel; Pratley, Richard E.; Cherney, David Z., I; McGuire, Darren K.; Cosentino, Francesco; Shih, Weichung J.; Liu, Jie; Frederich, Robert; Mancuso, James P.; Raji, Annaswamy; Gantz, Ira

authors

Pratley, Richard Edwin, MD

Publication Date

October 1, 2021

webpage

Web of Science

published in

BMJ OPEN DIABETES RESEARCH & CARE Journal

Research

keywords

chronic
diabetes mellitus
drug therapy
glycated hemoglobin A
kidney failure
type 2

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.